Paolo Dellabona

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3072642/publications.pdf

Version: 2024-02-01

112 papers	8,780 citations	53794 45 h-index	42399 92 g-index
116 all docs	116 docs citations	116 times ranked	11015 citing authors

#	Article	IF	Citations
1	Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment. Frontiers in Medicine, 2022, 9, .	2.6	15
2	Workflow for high-dimensional flow cytometry analysis of T cells from tumor metastases. Life Science Alliance, 2022, 5, e202101316.	2.8	2
3	Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2021, 27, 729-739.	7.0	5
4	Cytokine-Induced Memory-Like NK Cells with High Reactivity against Acute Leukemia Blasts and Solid Tumor Cells Suitable for Adoptive Immunotherapy Approaches. Cancers, 2021, 13, 1577.	3.7	5
5	Exploiting CD1-restricted T cells for clinical benefit. Molecular Immunology, 2021, 132, 126-131.	2.2	9
6	Flow cytometry data mining by cytoChain identifiesÂdeterminants of exhaustion and stemness in TCRâ€engineered T cells. European Journal of Immunology, 2021, 51, 1992-2005.	2.9	10
7	CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eî¼-TCL1 mice through a CD40L-independent mechanism. Blood Advances, 2021, 5, 2817-2828.	5.2	13
8	Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia. Nature Communications, 2021, 12, 4844.	12.8	3
9	miRâ€21 sustains CD28 signalling and lowâ€affinity Tâ€cell responses at the expense of selfâ€tolerance. Clinical and Translational Immunology, 2021, 10, e1321.	3.8	1
10	Mir106b-25 and Mir17-92 Are Crucially Involved in the Development of Experimental Neuroinflammation. Frontiers in Neurology, 2020, 11, 912.	2.4	5
11	Editorial: NKT Cells in Cancer Immunotherapy. Frontiers in Immunology, 2020, 11, 1314.	4.8	15
12	Boosting Interleukinâ€12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGRâ€Tagged Nanogold. Small, 2019, 15, e1903462.	10.0	21
13	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	2.9	766
14	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nature Communications, 2019, 10, 1065.	12.8	120
15	CD4+ T Cells Sustain Aggressive Chronic Lymphocytic Leukemia through a CD40L-Independent Mechanism. Blood, 2019, 134, 683-683.	1.4	0
16	Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. Cell Reports, 2018, 22, 3006-3020.	6.4	62
17	Potential advantages of CD1-restricted T cell immunotherapy in cancer. Molecular Immunology, 2018, 103, 200-208.	2.2	5
18	The Pathophysiological Relevance of the iNKT Cell/Mononuclear Phagocyte Crosstalk in Tissues. Frontiers in Immunology, 2018, 9, 2375.	4.8	17

#	Article	IF	Citations
19	T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. Gut, 2017, 66, 454-463.	12.1	48
20	Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. Blood, 2017, 129, 3440-3451.	1.4	56
21	Guidelines for the use of flow cytometry and cell sorting in immunological studies[*]. European Journal of Immunology, 2017, 47, 1584-1797.	2.9	505
22	Of selfâ€lipids, CD1â€restricted T cells, and contact sensitization. European Journal of Immunology, 2017, 47, 1119-1122.	2.9	1
23	Harnessing the CD1 restricted T cell response for leukemia adoptive immunotherapy. Cytokine and Growth Factor Reviews, 2017, 36, 117-123.	7.2	6
24	The circulating microRNome demonstrates distinct lymphocyte subsetâ€dependent signatures. European Journal of Immunology, 2016, 46, 725-731.	2.9	11
25	miR-17â^¼92 family clusters control iNKT cell ontogenesis via modulation of TGF-Î² signaling. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8286-E8295.	7.1	44
26	Alliance Against Cancer, the network of Italian cancer centers bridging research and care. Journal of Translational Medicine, 2015, 13, 360.	4.4	10
27	Group 1 <scp>CD1</scp>â€restricted T cells and the pathophysiological implications of selfâ€lipid antigen recognition. Tissue Antigens, 2015, 86, 393-405.	1.0	13
28	B Cell Help by CD1d-Rectricted NKT Cells. Antibodies, 2015, 4, 279-294.	2.5	5
29	Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. Cancer Immunology, Immunotherapy, 2015, 64, 99-104.	4.2	32
30	A Subset of CD8Î±Î²+ Invariant NKT Cells in a Humanized Mouse Model. Journal of Immunology, 2015, 195, 1459-1469.	0.8	11
31	Targeting leukemia by CD1c-restricted T cells specific for a novel lipid antigen. OncoImmunology, 2015, 4, e970463.	4.6	11
32	iNKTâ€cell help to B cells: A cooperative job between innate and adaptive immune responses. European Journal of Immunology, 2014, 44, 2230-2237.	2.9	32
33	A novel self-lipid antigen targets human T cells against CD1c+ leukemias. Journal of Experimental Medicine, 2014, 211, 1363-1377.	8.5	80
34	Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cellâ€“Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4. Journal of Immunology, 2014, 192, 523-532.	0.8	97
35	Functional Education of Invariant NKT Cells by Dendritic Cell Tuning of SHP-1. Journal of Immunology, 2013, 190, 3299-3308.	0.8	10
36	Intracellular Modulation, Extracellular Disposal and Serum Increase of MiR-150 Mark Lymphocyte Activation. PLoS ONE, 2013, 8, e75348.	2.5	66

#	Article	IF	Citations
37	Abstract A83: Modifications of the bone marrow microenvironment in the transition from monoclonal gammopathy of undetermined significance to multiple myeloma in Vk*MYC mice.. , 2013, , .		0
38	Invariant natural killer T cells reconstitution and the control of leukemia relapse in pediatric haploidentical hematopoietic stem cell transplantation. OncoImmunology, 2012, 1, 355-357.	4.6	19
39	Loss of T cell microRNA provides systemic protection against autoimmune pathology in mice. Journal of Autoimmunity, 2012, 38, 39-48.	6.5	19
40	Follicular Helper NKT Cells Induce Limited B Cell Responses and Germinal Center Formation in the Absence of CD4+ T Cell Help. Journal of Immunology, 2012, 188, 3217-3222.	0.8	90
41	Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation. Best Practice and Research in Clinical Haematology, 2011, 24, 339-349.	1.7	17
42	On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies. Clinical Immunology, 2011, 140, 152-159.	3.2	26
43	Highâ€frequency and adaptiveâ€like dynamics of human CD1 selfâ€reactive T cells. European Journal of Immunology, 2011, 41, 602-610.	2.9	116
44	Fine tuning by human CD1e of lipid-specific immune responses. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14228-14233.	7.1	51
45	Invariant NKT Cell Reconstitution in Pediatric Leukemia Patients Given HLA-Haploidentical Stem Cell Transplantation Defines Distinct CD4+ and CD4â^' Subset Dynamics and Correlates with Remission State. Journal of Immunology, 2011, 186, 4490-4499.	0.8	85
46	An unexpected requirement for CD4⁺ T cells in antiâ€glycolipid antibody responses. Immunology and Cell Biology, 2011, 89, 499-501.	2.3	1
47	The CD4⁺ Tâ€cell epitopeâ€binding register is a critical parameter when generating functional HLAâ€DR tetramers with promiscuous peptides. European Journal of Immunology, 2010, 40, 1603-1616.	2.9	6
48	iNKT Cells Control Mouse Spontaneous Carcinoma Independently of Tumor-Specific Cytotoxic T Cells. PLoS ONE, 2010, 5, e8646.	2.5	61
49	An Efficient Strategy to Induce and Maintain In Vitro Human T Cells Specific for Autologous Non-Small Cell Lung Carcinoma. PLoS ONE, 2010, 5, e12014.	2.5	3
50	T helper 17 T cells do good for cancer immunotherapy. Immunotherapy, 2010, 2, 21-24.	2.0	16
51	Invariant TCR Rather Than CD1d Shapes the Preferential Activities of C-Glycoside Analogues Against Human Versus Murine Invariant NKT Cells. Journal of Immunology, 2009, 183, 4415-4421.	0.8	32
52	Dicer-Dependent MicroRNA Pathway Controls Invariant NKT Cell Development. Journal of Immunology, 2009, 183, 2506-2512.	0.8	82
53	The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. Journal of Experimental Medicine, 2009, 206, 735-742.	8.5	53
54	NKT-cell help to B lymphocytes can occur independently of cognate interaction. Blood, 2009, 113, 370-376.	1.4	87

#	Article	IF	Citations
55	B Cell Helper Assays. Methods in Molecular Biology, 2009, 514, 15-26.	0.9	1
56	The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. Journal of Cell Biology, 2009, 185, i1-i1.	5.2	0
57	Use of MHC class II tetramers to investigate CD4⁺ T cell responses: Problems and solutions. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2008, 73A, 1010-1018.	1.5	29
58	Phage displayâ€derived recombinant antibodies with TCRâ€like specificity against Î±â€galactosylceramide and its analogues in complex with human CD1d molecules. European Journal of Immunology, 2008, 38, 829-840.	2.9	15
59	Selective activation, expansion, and monitoring of human iNKTâ€„cells with a monoclonal antibody specific for the TCR Î±â€chain CDR3 loop. European Journal of Immunology, 2008, 38, 1756-1766.	2.9	89
60	Serological Immunoreactivity against Colon Cancer Proteome Varies upon Disease Progression. Journal of Proteome Research, 2008, 7, 504-514.	3.7	20
61	Carcinoembryonic Antigen-Specific but Not Antiviral CD4+ T Cell Immunity Is Impaired in Pancreatic Carcinoma Patients. Journal of Immunology, 2008, 181, 6595-6603.	0.8	97
62	Innate-Like Effector Differentiation of Human Invariant NKT Cells Driven by IL-7. Journal of Immunology, 2008, 180, 4415-4424.	0.8	27
63	Invariant NKT cells sustain specific B cell responses and memory. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3984-3989.	7.1	213
64	CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells. Blood, 2007, 110, 251-258.	1.4	47
65	Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood, 2006, 108, 3843-3850.	1.4	45
66	Cutting Edge: Influence of the TCR VÎ² Domain on the Selection of Semi-Invariant NKT Cells by Endogenous Ligands. Journal of Immunology, 2006, 176, 2064-2068.	0.8	70
67	Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation. Experimental Hematology, 2005, 33, 212-218.	0.4	14
68	Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides. BMC Immunology, 2005, 6, 24.	2.2	18
69	Targeted Expression of Human CD1d in Transgenic Mice Reveals Independent Roles for Thymocytes and Thymic APCs in Positive and Negative Selection of VÎ±14i NKT Cells. Journal of Immunology, 2005, 175, 7303-7310.	0.8	55
70	Production of Profibrotic Cytokines by Invariant NKT Cells Characterizes Cirrhosis Progression in Chronic Viral Hepatitis. Journal of Immunology, 2004, 173, 1417-1425.	0.8	141
71	Activation of invariant NKT cells by Î±GalCer administration protects mice from MOG35â€“55-induced EAE: critical roles for administration route and IFN-Î³. European Journal of Immunology, 2003, 33, 1830-1838.	2.9	132
72	CD1d-restricted Help To B Cells By Human Invariant Natural Killer T Lymphocytes. Journal of Experimental Medicine, 2003, 197, 1051-1057.	8.5	217

#	Article	IF	Citations
73	Innate immune responses support adaptive immunity: NKT cells induce B cell activation. Vaccine, 2003, 21, S48-S54.	3.8	41
74	Human Invariant VÎ±24-JÎ±Q TCR Supports the Development of CD1d-Dependent NK1.1+ and NK1.1â^' T Cells in Transgenic Mice. Journal of Immunology, 2003, 170, 2390-2398.	0.8	29
75	The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Research, 2003, 63, 2158-63.	0.9	34
76	CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Research, 2003, 63, 8481-6.	0.9	45
77	Laparoscopic Versus Open Colorectal Surgery. Annals of Surgery, 2002, 236, 759-767.	4.2	416
78	T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. European Journal of Immunology, 2002, 32, 2046.	2.9	109
79	Laparoscopic versus open colorectal surgery: a randomized trial on short-term outcome. Annals of Surgery, 2002, 236, 759-66; disscussion 767.	4.2	250
80	CD28 and LFA-1 contribute to cyclosporin A-resistant T cell growth by stabilizing the IL-2 mRNA through distinct signaling pathways. European Journal of Immunology, 2000, 30, 1136-1144.	2.9	33
81	Neonatal invariant VÎ±24+ NKT lymphocytes are activated memory cells. European Journal of Immunology, 2000, 30, 1544-1550.	2.9	108
82	Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma. Journal of Immunology, 2000, 165, 2651-2656.	0.8	127
83	Vaccination with Mouse Mammary Adenocarcinoma Cells Coexpressing B7-1 (CD80) and B7-2 (CD86) Discloses the Dominant Effect of B7-1 in the Induction of Antitumor Immunity. Journal of Immunology, 2000, 164, 698-704.	0.8	23
84	Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11. Journal of Experimental Medicine, 1999, 189, 871-876.	8.5	204
85	T-cell clonality in immune responses. Trends in Immunology, 1999, 20, 262-266.	7.5	115
86	Vascular attack and immunotherapy: a â€˜two hitsâ€™ approach to improve biological treatment of cancer. Gene Therapy, 1999, 6, 153-154.	4.5	6
87	Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for VÎ±24+ T cells and rapid elimination of effector cells by apoptosis. European Journal of Immunology, 1998, 28, 3448-3455.	2.9	161
88	Age-related modifications of the human alphabeta T cell repertoire due to different clonal expansions in the CD4+ and CD8+ subsets. International Immunology, 1998, 10, 1281-1288.	4.0	159
89	CD1d-mediated Recognition of an Î±-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution. Journal of Experimental Medicine, 1998, 188, 1521-1528.	8.5	597
90	Human Melanoma Cells Transfected with the B7-2 Co-Stimulatory Molecule Induce Tumor-Specific CD8⁺Cytotoxic T LymphocytesIn Vitro. Human Gene Therapy, 1998, 9, 1335-1344.	2.7	25

#	Article	IF	Citations
91	An improved PCR-heteroduplex method permits high-sensitivity detection of clonal expansions in complex T cell populations. Journal of Immunological Methods, 1996, 196, 181-192.	1.4	51
92	Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. European Journal of Immunology, 1996, 26, 1851-1859.	2.9	52
93	Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. European Journal of Immunology, 1995, 25, 1154-1162.	2.9	111
94	Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro. International Immunology, 1995, 7, 1741-1752.	4.0	29
95	Dual Receptor T-Cells.. Annals of the New York Academy of Sciences, 1995, 756, 66-70.	3.8	25
96	An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells.. Journal of Experimental Medicine, 1994, 180, 1171-1176.	8.5	427
97	MAGE-1 gene product is a cytoplasmic protein. International Journal of Cancer, 1994, 59, 435-439.	5.1	54
98	In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. European Journal of Immunology, 1994, 24, 2691-2698.	2.9	45
99	On the Relative Roles of Interleukin-2 and Interleukin-10 in the Generation of Lymphokine-Activated Killer Cell Activity. Cellular Immunology, 1993, 146, 391-405.	3.0	36
100	Expression of two T cell receptor alpha chains: dual receptor T cells. Science, 1993, 262, 422-424.	12.6	486
101	In vivo persistence of expanded clones specific for bacterial antigens within the human T cell receptor alpha/beta CD4-8- subset.. Journal of Experimental Medicine, 1993, 177, 1763-1771.	8.5	140
102	Structure of the TCR-Ag-MHC Complex. , 1992, , 17-23.		1
103	A single amino acid substitution in the Ak molecule fortuitously provokes an alloresponse. European Journal of Immunology, 1991, 21, 209-213.	2.9	9
104	A family of trans-acting factors with distinct regulatory functions control expression of MHC class II genes. Immunologic Research, 1990, 9, 20-33.	2.9	7
105	Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific monoclonal antibodies.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2941-2945.	7.1	20
106	Superantigens interact with MHC class II molecules outside of the antigen groove. Cell, 1990, 62, 1115-1121.	28.9	452
107	Fc receptor triggering induces expression of surface activation antigens and release of platelet-activating factor in large granular lymphocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 2443-2447.	7.1	65
108	Platelet cationic proteins are present in glomeruli of lupus nephritis patients. Kidney International, 1986, 30, 555-565.	5.2	21

#	Article	IF	Citations
109	Definition by CB12 monoclonal antibody of a differentiation marker specific for human monocytes and their bone marrow precursors. Cellular Immunology, 1986, 97, 276-285.	3.0	9
110	Functional and molecular characterization by the CB04 monoclonal antibody of a cell surface structure exerting C3-complement receptor activity. Journal of Clinical Immunology, 1985, 5, 412-420.	3.8	16
111	Murine monoclonal antibodies as probes for the phenotypical, functional, and molecular analysis of a discrete peripheral blood lymphocyte population exerting natural killer activity in vitro. Human Immunology, 1985, 14, 87-102.	2.4	35
112	Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells. Human Immunology, 1984, 9, 9-20.	2.4	95